AiVita Biomedical
PrivateLast Round
Series B
Extension
Dec 29, 2020
Total Funding Raised
$60.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
AiVita Biomedical operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Series B Extension round in December 2020.
AiVita Biomedical is a biotechnology company that develops personalized vaccines for infectious diseases and cancer treatment, as well as innovative vaccine kits for pathogen readiness.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Fashion & Beauty, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AiVita Biomedical Comparables
Compare AiVita Biomedical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Amphera B.V. | 73% | |
| Diakonos Oncology | 72% | |
| CellResearch Corporation | 72% |
For institutional investors. Book with your work email.
AiVita Biomedical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Dec 29, 2020 | ||||
| Series B | Feb 25, 2020 | ||||
| Grant | Jul 17, 2018 | ||||
| Series B | Jun 11, 2018 | ||||
| Grant | Sep 29, 2016 | ||||
Grant | Jul 7, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AiVita Biomedical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Eye Institute (NIH) | Grant |
| NIH RADx | Grant |
| California Technology Ventures | Series A |
| California Institute for Regenerative Medicine | Grant |
| National Eye Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 84% MoM, reaching 3K.
- Dec 29, 2020
Raised $25M in a Series B Extension round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 18, 2026
AIVITA Biomedical, Inc. appoints physician, epidemiologist, and global health leader Larry Brilliant, M.D., M.P.H., to its board of directors in California on Aug 18th '26, strengthening its leadership as it advances its multi-pathogen vaccine program.
- recognized_asAug 13, 2026
Hans S. Keirstead at AIVITA Biomedical, Inc. recognized as 2026 Prix Galien USA nominee in the "Best Startup" category at Prix Galien USA Awards on Jul 1st '26.
- receives_awardAug 13, 2026
On Aug 13th '26 in California, AIVITA Biomedical, Inc. is named a 2026 Prix Galien USA nominee in the Best Startup category by The Galien Foundation for its personalized immunotherapy platform, with winners honored at the awards ceremony on Oct 29th '26 in New York City.
For institutional investors. Book with your work email.
AiVita Biomedical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AiVita Biomedical's valuation, stock price, and market status.
Is AiVita Biomedical a public or private company?
AiVita Biomedical is a private company.
What is the current stock price of AiVita Biomedical?
AiVita Biomedical is a private company, so its shares have no public market price. Caplight tracks AiVita Biomedical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AiVita Biomedical worth (valuation)?
Valuation information for AiVita Biomedical is not publicly available.
Can I buy AiVita Biomedical stock?
AiVita Biomedical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AiVita Biomedical's last funding round?
AiVita Biomedical's most recent funding round was Series B Extension on December 29, 2020.
Who are the main investors in AiVita Biomedical?
Key investors in AiVita Biomedical include California Technology Ventures.
Will AiVita Biomedical IPO soon?
No public IPO plans have been announced for AiVita Biomedical.
How can I track AiVita Biomedical secondary market activity?
Caplight tracks bids, offers, and trades in AiVita Biomedical's shares on secondary markets.